ORR of some patients reaches 100% Rongchang Biotech announces the latest research data of ADC velicitumumab

On February 17, during the 2022 American Society of Clinical Oncology Symposium on Genitourinary Oncology (ASCO-GU), Rongchang Biologics announced its HER2-targeted antibody-drug conjugate (ADC) vedicitumab combination therapy for the treatment of topical Recent clinical advances in advanced or metastatic urothelial carcinoma

Urothelial carcinoma is a highly malignant tumor with limited treatment options for patients who have failed platinum-based chemotherapy

The study showed that patients benefited from the combination therapy of vedicitumab and toripalimab regardless of the number of lines of treatment, HER2 and PD-L1 expression status, and ORR was significantly correlated with HER2 or PD -L1 is highly expressed and elevated

In addition to the indications for urothelial cancer, vellicitumab has also achieved good data in clinical trials for the treatment of HER2-expressing advanced gastric cancer, breast cancer and other tumors

Rongchang Bio's press release pointed out that Vidicitumumab is coupled with a highly efficient cytotoxic molecule MMAE on the monoclonal antibody against HER2, giving it three advantages: first, it has a stronger affinity with the HER2 receptor; Second, it not only accurately kills tumor cells with HER2 receptors, but also produces a para-killing effect, thereby killing tumor cells with low HER2 expression; third, the cleavable linker can target immunosuppressive cells, making Vidi Potential synergy exists between cetuximab and immunotherapy drugs

It is hoped that Vidicitumab will progress smoothly in the next clinical trials and benefit more patients as soon as possible

References:

[1] Too hardcore! Rongchang Biotech's latest study of vedicitumab appeared in ASCO-GU, and the objective response rate of these patients was 100%.